BLAINTRAVENOUSINJECTABLE
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ASPARLAS (calaspargase pegol) by R-Pharm US is l-asparaginase is an enzyme that catalyzes the conversion of the amino acid l-asparagine into aspartic acid and ammonia. Approved for acute lymphoblastic leukemia. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASPARLAS (calaspargase pegol) is a pegylated L-asparaginase enzyme used to treat asparagine-dependent hematologic malignancies, primarily acute lymphoblastic leukemia and related T-cell lymphomas. It depletes plasma asparagine, starving leukemic cells with low asparagine synthetase expression. The pegylation reduces immunogenicity compared to native asparaginase, improving tolerability and efficacy.
Peak
Product is at peak commercial phase with established market presence; brand teams likely stable in size with focus on market maintenance rather than growth.
Mechanism of Action
L-asparaginase is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of ASPARLAS is thought to be based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of…
Pharmacologic Class:
Asparagine-specific Enzyme
Indications (1)
Clinical Trials (2)
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Started Aug 2022
15 enrolled
Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v8+4 more
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Started Jul 2021
42 enrolled
Acute Lymphoblastic Leukemia
Worked on ASPARLAS at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.